The article describes the rapidly increasing use of GLP-1 receptor agonists for weight loss, with an estimated 1 in 50 adults in the UK taking them. These drugs were approved based on studies that showed a reduction in body weight of approximately 15–20% and an improvement in obesity-related comorbidities. The authors refer to a systematic review of studies that followed people after treatment with weight management drugs. These studies show that, on average, patients regain about two-thirds of the weight they lost within one year of stopping treatment. It is assumed that after approximately 1.5 years from the end of the treatment, they will achieve an almost full return to their original weight. A possible solution is to continue treatment long-term, similar to other cardiometabolic risk factors such as high blood pressure. The central question of the article is whether health care systems can financially afford the long-term administration of these effective but expensive drugs.